

Anthea C Peters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3626379/publications.pdf>

Version: 2024-02-01

38
papers

503
citations

840119

11
h-index

713013

21
g-index

38
all docs

38
docs citations

38
times ranked

892
citing authors

#	ARTICLE	IF	CITATIONS
1	Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities. <i>Leukemia and Lymphoma</i> , 2022, 63, 583-590.	0.6	5
2	Tumor infiltrating lymphocytes predict survival in solid organ transplant recipients with monomorphic post-transplant lymphoproliferative disorders. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	1
3	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 4003-4017.	3.2	15
4	Gene Methylation and Silencing of WIF1 Is a Frequent Genetic Abnormality in Mantle Cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 893.	1.8	1
5	Expanded antigen-experienced CD160 ⁺ CD8 ⁺ effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia. , 2021, 9, e002189.		23
6	Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2021, 96, 764-771.	2.0	46
7	Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism. <i>Current Issues in Molecular Biology</i> , 2021, 43, 313-323.	1.0	3
8	Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada. <i>Blood</i> , 2021, 138, 3744-3744.	0.6	0
9	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 183-183.	0.6	8
10	Classic Hodgkin lymphoma post-transplant lymphoproliferative disorders (PTLD) are often preceded by discordant PTLD subtypes. <i>Leukemia and Lymphoma</i> , 2020, 61, 3319-3330.	0.6	5
11	Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 2492-2496.	0.6	0
12	IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1653-1659.	0.6	6
13	Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder. <i>British Journal of Haematology</i> , 2020, 189, 97-105.	1.2	12
14	Lack of Effectiveness of Intravenous High-Dose Methotrexate for Prevention of CNS Relapse in Patients with High-Risk DLBCL: A Retrospective Analysis from Alberta, Canada. <i>Blood</i> , 2020, 136, 26-27.	0.6	7
15	Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. <i>Leukemia and Lymphoma</i> , 2019, 60, 133-141.	0.6	16
16	Epstein-Barr virus associated smooth muscle tumors in solid organ transplant recipients: Incidence over 31 years at a single institution and review of the literature. <i>Transplant Infectious Disease</i> , 2019, 21, e13010.	0.7	24
17	Epidemiology of Post-Transplant Lymphoproliferative Disorders in Children with Solid Organ Transplant over 34 Years of a Single Center Experience. <i>Blood</i> , 2019, 134, 1602-1602.	0.6	1
18	The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years. <i>Transplantation</i> , 2018, 102, 1553-1562.	0.5	59

#	ARTICLE	IF	CITATIONS
19	The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 829-835.	0.2	2
20	Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model. <i>Cancers</i> , 2018, 10, 206.	1.7	16
21	Posttransplant Lymphoproliferative Disorder After Clinical Islet Transplantation: Report of the First Two Cases. <i>American Journal of Transplantation</i> , 2017, 17, 2474-2480.	2.6	7
22	The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease. <i>European Journal of Haematology</i> , 2016, 97, 471-478.	1.1	5
23	Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia. <i>Leukemia Research</i> , 2016, 45, 47-52.	0.4	4
24	Epstein-Barr Virus Infection and Lymphoproliferative Disorders After Transplantation. , 2016, , 477-512.		2
25	Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 941-948.	2.0	6
26	CD3 T-Cell Infiltrates at Diagnosis Predicts Overall Survival in Solid Organ Transplant Recipients with Post-Transplant Lymphoproliferative Disorders (PTLD). <i>Blood</i> , 2016, 128, 1873-1873.	0.6	0
27	Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2015, 6, 181.	0.5	19
28	Morphologic Evolution in Post-Transplant Lymphoproliferative Disorders (PTLD): A Clinicopathologic Case Series. <i>Blood</i> , 2015, 126, 5008-5008.	0.6	0
29	Epidemiology Of Post-Transplant Lymphoproliferative Disorders Following Solid Organ Transplant In a Major Canadian Transplant Centre. <i>Blood</i> , 2013, 122, 4281-4281.	0.6	0
30	Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. <i>Leukemia and Lymphoma</i> , 2011, 52, 2124-2129.	0.6	12
31	Lymphopenia and EBER-Negativity Predict Poor Survival in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD) Treated in the Rituximab Era. <i>Blood</i> , 2011, 118, 1645-1645.	0.6	2
32	Autologous Stem Cell Transplantation Is a Curative Treatment Modality for Relapsed or Refractory Follicular Lymphoma, and Both Recent Rituximab Exposure and Follicular Lymphoma International Prognostic Index (FLIPI) ≥ 1 Scores Predict Improved Outcome. <i>Blood</i> , 2010, 116, 687-687.	0.6	9
33	Biological and clinical significance of GSK-3beta in mantle cell lymphoma—an immunohistochemical study. <i>International Journal of Clinical and Experimental Pathology</i> , 2010, 3, 244-53.	0.5	19
34	Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. <i>Blood</i> , 2008, 112, 5171-5179.	0.6	82
35	Epigenetic Regulation of the WNT Canonical Pathway in Mantle Cell Lymphoma.. <i>Blood</i> , 2008, 112, 3340-3340.	0.6	0
36	DNA Mismatch Repair Protein Msh6 Is Required for Optimal Levels of Ultraviolet-B-Induced Apoptosis in Primary Mouse Fibroblasts. <i>Journal of Investigative Dermatology</i> , 2003, 121, 876-880.	0.3	24

#	ARTICLE	IF	CITATIONS
37	Mammalian DNA mismatch repair protects cells from UVB-induced DNA damage by facilitating apoptosis and p53 activation. <i>DNA Repair</i> , 2003, 2, 427-435.	1.3	50
38	DNA Instability and Human Disease. <i>Molecular Diagnosis and Therapy</i> , 2001, 1, 21-28.	3.3	12